31 completed, 5 terminated, 5 unknown, 3 recruiting. 46 Phase 2, 10 Phase 1, 7 Phase 3.
Follow Imiquimod: new trials by email Literature Review of Imiquimod trials Research Report on Imiquimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients Imiquimod 5% cream, Nivolumab - Vulvar Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Centre Leon Berard | 50 | 2026-09-01 | 2026-09-30 |
| Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma cemiplimab, Topical imiquimod - Cutaneous Basal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Instituto Oncológico Dr Rosell | 18 | 2025-10-22 | 2025-12-01 |
| Topical Imiquimod Treatment of Oral Dysplasia Imiquimod (topical use) - Oral Dysplasia, Leukoplakia Oral | Phase 1 / Phase 2 | Recruiting | University of Southern California | 20 | 2025-10-01 | 2026-03-04 |
| HPV Vaccine, Imiquimod, and Metformin Combination Trial HPV vaccine, Imiquimod, and metformin combination therapy - Cervical Carcinoma, Vaginal Carcinoma | Phase 2 | Recruiting | Baylor College of Medicine | 85 | 2024-08-23 | 2024-11-13 |
| Gene and Protein Expression Profiles After Treatment of Actinic Keratoses 5Fluorouracil, Imiquimod, Melatonin - Actinic Keratoses | Phase 2 | Unknown | Ismail Gögenur | 48 | 2023-02-01 | 2023-02-23 |
| Efficacy of Tazarotene in Treatment of Verruca Plana Tazarotene 0.1% Gel,Top, Imiquimod, Fluorouracil Cream - Warts Flat | Phase 2 | Unknown | Zagazig University | 80 | 2022-04-15 | 2022-05-16 |
| Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients Intradermal hepatitis B vaccine with imiquimod, Intramuscular hepatitis B vaccine with aqueous cream - Inflammatory Bowel Diseases, Hepatitis B | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 104 | 2019-08-12 | 2022-05-18 |
| A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma Sonidegib, Imiquimod, Surgery - Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified | Phase 2 | Completed | Melanoma Institute Australia | 16 | 2019-07-23 | 2025-12-16 |
| Imiquimod for Preventing Keloid Recurrence Imiquimod 5% cream - Keloid | Phase 2 | Terminated | University of Pennsylvania | 6 | 2019-02-05 | 2020-11-19 |
| Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions Control, Imiquimod - High Grade Intraepithelial Neoplasia, Cervix Cancer | Phase 2 | Completed | Barretos Cancer Hospital | 90 | 2018-01-01 | 2021-02-17 |
| Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000 - Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia | Phase 2 | Completed | Inovio Pharmaceuticals | 33 | 2017-08-31 | 2023-08-25 |
| Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream - Progressive Solid Malignancies, Refractory Solid Malignancies | Phase 1 / Phase 2 | Terminated | Kiromic BioPharma Inc. | 3 | 2017-07-28 | 2020-04-24 |
| Imiquimod and Influenza Vaccine for Immunocompromised Patients Intanza, Mutagrip, Aldara - Influenza Vaccine | Phase 2 | Completed | University of Lausanne Hospitals | 70 | 2016-11-01 | 2017-10-10 |
| iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL Peptide Vaccine, Imiquimod - Leukemia, Chronic Lymphatic | Phase 2 | Completed | University Hospital Tuebingen | 56 | 2016-10-05 | 2022-11-28 |
| ID HBV Vaccination With Imiquimod in OBI Imiquimod + ID HBVv, Aqueous + ID HBVv, Imiquimod + IM HBVv - Hepatitis B | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 120 | 2016-10-01 | 2019-10-22 |
| Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) 9-valent HPV vaccine, Imiquimod - Cervical Intraepithelial Neoplasia, Cervical Dysplasia | Phase 2 | Completed | Yale University | 134 | 2016-07-01 | 2024-05-02 |
| Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL Individual peptide vaccination with adjuvant GM-CSF and Imiquimod - Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults | Phase 1 / Phase 2 | Completed | University Children's Hospital Tuebingen | 30 | 2016-06-01 | 2023-12-04 |
| HBV Vaccine in Renal Failure Patients Intradermal HBVv with imiquimod, Intradermal HBVv with aqueous cream, Intramuscular HBVv with aqueous cream - Renal Failure | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 94 | 2016-01-01 | 2019-10-22 |
| Efficacy and Tolerability of Topical LFX453 for External Genital Warts Investigational Treatment, Aldara - External Genital Warts | Phase 2 | Completed | Novartis Pharmaceuticals | 88 | 2015-05-12 | 2021-01-05 |
Showing 20 of 46. Sign in to see all of them.
Keratosis, Actinic (5) · Melanoma (4) · Uterine Cervical Dysplasia (4) · Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Glioblastoma (2) · Hemangioma, Capillary (2) · Hepatitis B (2) · Neoplasms (2) · Papillomavirus Infections (2) · Astrocytoma (1) · Bowen's Disease (1) · Brain Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma in Situ (1)
The University of Hong Kong (3) · Medical University of Vienna (2) · NYU Langone Health (2) · University Hospital Tuebingen (2) · Alliance for Clinical Trials in Oncology (1) · Barretos Cancer Hospital (1) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Brooke Army Medical Center (1) · CONRAD (1) · Centre Leon Berard (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Cytos Biotechnology AG (1) · Foundation Fader (1) · German Cancer Research Center (1)
United States (22) · Germany (5) · Austria (3) · Belgium (2) · Hong Kong (2) · Switzerland (2) · Australia (1) · Bolivia (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Denmark (1) · Egypt (1) · France (1)
Sylvia Adams, MD (2) · Addie N Alkhas, MD (1) · Alessandro D Santin, MD (1) · Andrea Mayer-Mokler (1) · Andrea R Thurman, MD (1) · Anthony Tolcher, MD (1) · Arnulf Stenzl, Prof. (1) · Baurain Jean-Francois, MD, PhD (1) · Bernard Fox, PhD (1) · Bobbie S. Gostout, MD (1) · Bruno DO Fonseca, MD (1) · Catherine McCuaig, M.D. (1) · David Avigan, MD (1) · Georg Stingl, Prof. (1) · Henry C. Vasconez, MD (1)
PMID 21907959, PMID 22914404, PMID 11595691, PMID 15863172, PMID 16174242, PMID 16473126, PMID 17655918, PMID 18385498, PMID 18407790, PMID 18801868, PMID 19419474, PMID 19640281, PMID 20556751, PMID 21288852, PMID 21377898, PMID 21530398, PMID 22742517, PMID 22767669, PMID 23042206, PMID 23276555, PMID 23380265, PMID 23489374, PMID 23843155, PMID 24201682, PMID 24264713, PMID 24411029, PMID 28114604, PMID 28341495, PMID 32556176, PMID 33957649, PMID 35546255, PMID 39660140, PMID 40187749
2015 (1), 2016 (1), 2025 (1), R01CA138521 (1), R01CA161891 (1), R44CA121612 (1)